Combination treatment of patients with metabolic phenotype of osteoarthritis: an exploratory study

Treatment of osteoarthritis (OA) patients with comorbidities can be challenging due to adverse events and non-sufficient efficacy of modern drugs. A safe and effective alternative could be the methods of traditional medicine and their combinations. The aim of this study was to evaluate efficacy and safety of combination of curcuma-based parapharmaceutical preparation and acupuncture in metabolic phenotype of OA (MPOA). The trial design was pilot open-label “before – after” study with the duration of 12 weeks. The patients with MPOA received parapharmaceutical preparation Epigenorm Antivir in a daily dose of 1000 mg and underwent 15-20 sessions of classical acupuncture. We enrolled twenty three women with metabolic syndrome (MS), clinical and radiographic signs of gonarthrosis, mean age 66.5 years, mean body mass index 34.5. At the end of treatment there was a decrease in pain levels according to visual analogue scale (VAS) (before 65 (12.7), after 24.6 (21.0), р=0.001), WOMAC pain scale (before 210.6 (102.2), after 103 (80.8), p = 0.014), KOOS (before 47.8 (12.1), after 66.7 (16.2), р = 0.001). The treatment resulted in statistically significant improvement of daily and social activities, role functioning, and quality of life. The results were clinically significant as evidenced by the moderate (Cohen d > 0.5) and large (Cohen d > 0.8) effect sizes of most outcome changes in accordance with the Cohen classification. The clinical improvement was accompanied by the decrease in MS components – LDL cholesterol (before 3.26 (0.26) mmol/l, after 2.43 (0.2) mmol/l, р = 0.001), triglycerides (before 2.02 (0.16) mmol/l, after 1.31 (0.1) mmol/l, р = 0.005). The treatment resulted in the reduction of systemic inflammation as evidenced by the decrease in the concentrations of TNFα (before 15.9 (1.2) pg/ml, after 12.4 (0.8), р = 0.002), histamine (before 1.6 (0.2) ng/ml, after 0.7 (0.2) pg/ml, р = 0.034), IL-18 (before 208.8 (32.6 ) pg/ml, after 160.0 (26.0) pg/ml, р = 0.002) and CRP (before 6.05 (1.3) mg/l, after 3.2 (0.7) mg/l, р = 0.022). At the same time there was an increase of concentration of IL-10 (before 1.5 (0.7) pg/ml, after 3.8 (1.2), р = 0,006) and adiponectin (before 34.0 (5.6) pg/ml, after 40.0 (6.9), р = 0.034). The treatment was well tolerated, no serious adverse events were registered. The pleiotropic actions of combination treatment occured probably due to synergistic effects of herbal therapies and acupunctures. The results provide a rationale for larger scale, randomized controlled double-blind clinical trials.

1. Alekseeva L.I., Taskina E.A., Kashevarova N.G., Sharapova E.P., Anikin S.G., Strebkova E.A., Korotkova T.A., Raskina T.A., Zonova E.V., Otteva E.N. Knee osteoarthritis and metabolic syndrome: new approaches to therapy. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice, 2018, Vol. 56, no. 2, pp. 157-163. (In Russ.)

2. Genkel V.V., Kuznetsova A.S., Sumerkina V.A., Salashenko A.O., Lebedev E.V., Shaposhnik I.I. Increase in highsensitive C-reactive protein as a marker of polyvascular disease in patients with cardiovascular diseases. Meditsinskiy sovet = Medical Council, 2019, Vol. 16, pp. 86-93. (In Russ.)

3. Golovach I.Yu., Metabolic phenotype of osteoarthritis. Current views on pathogenesis, mechanisms of progression, and treatment approaches. Ukrainskiy revmatologicheskiy zhurnal = Ukrainian Journal of Rheumatology, 2018, no. 71 (1). (In Russ.)

4. Diagnosis and treatment of metabolic syndrome. In book: Collection of National Clinical Recommendations. Moscow: Silitseya-Poligraf, 2009, pp. 106-143.

5. Korshunov N.I., Rechkina E.V., Filatova Yu.S., Yaltseva N.V. Osteoarthritis and depression. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice, 2018, Vol. 56, no. 1, pp. 93-98. (In Russ.)

6. Rudoy A.S., Chernysh O. V. Metabolic syndrome: a modern view on the problem. Voennaya meditsina = Military Medicine, 2016, no. 1, pp. 107-114. (In Russ.)

7. Savkin I.V., Goldina I.A. Clinical efficiency of nutriceutics with the epigenom-directed action at the metabolic syndrome. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2018, Vol. 12, no. 4, pp. 736-738. (In Russ.)

8. Tarlovskaya E.I. Comorbidity and polymorbidity – a modern interpretation and urgent tasks facing the therapeutic community. Kardiologiya = Cardiology, 2018, Vol. 58 (9S), pp. 29-38. (In Russ.)

9. Shirinsky V.S., Velichkina O.V., Shirinsky I.V., Kozlov V.A. Efficacy of acupuncture in patients with diabetes-associated osteoarthritis. Vestnik Novosibirskogo gosudarstvennogo universiteta. Seriya: Biologiya, klinicheskaya medicina = Bulletin of Novosibirsk State University. Series: Biology, Clinical Medicine, 2015, Vol. 13, no. 3, pp. 25-30. (In Russ.)

10. Shirinsky V.S., Kazygasheva E.V., Shirinsky I.V. Inflammation and immunity: a role of pathogenesis of osteoarthritis. Meditsinskaya immunologiya = Medical Immunology (Russia), 2019, Vol. 21, no. 1, pp. 39-48. (In Russ.) doi: 10.15789/1563-0625-2019-1-39-48.

11. Shirinsky V.S., Kalinovskaya N.Yu., Filatova K.Yu., Shirinsky I.V. Clinical and immunological features of metabolic phenotype of osteoarthritis. Meditsinskaya immunologiya = Medical Immunology (Russia), 2020, Vol. 22, no. 2, pp. 327-334. (In Russ.) doi: 10.15789/1563-0625-CAI-1881.

12. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol., 1988, no. 15, pp. 1833-1840.

13. Berenbaum F., Griffin T.M., Liu-Bryan R. Metabolic regulation of inflammati on in osteoarthritis. Arthritis Rheum., 2017, Vol. 69, no.1, pp. 9-21.

14. Boyanapalli S.S., Tony Kong A.N. “Curcumin, the king of spices”: epigenetic regulatory mechanisms in the prevention of cancer, neurological, and inflammatory diseases. Curr. Pharmacol. Rep., 2015, Vol. 1, pp. 129-139.

15. Buhrmann C., Mobasheri A., Busch F., Aldinger C., Stahlmann R., Montaseri A., Shakibaei M. Curcumin modulates nuclear factor kappa B-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem., 2011, Vol. 286, no. 32, pp. 28556-28566.

16. de Lange-Brokaar B.J., Kloppenburg M., Andersen S.N., Dorjée A.L., Yusuf E., Herb-van Toorn L., Kroon H.M., Zuurmond A.M., Stojanovic-Susulic V., Bloem J.L., Nelissen R.G., Toes R.E., Ioan-Facsinay A. Characterization of synovial mast cells in knee osteoarthritis: association with clinical parameters. Osteoarth. Cartilage, 2016, Vol. 24, no. 4, pp. 664-671.

17. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctôt K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry, 2010, Vol. 1, no. 67 (5), pp. 446-457.

18. Harvey A.L., Edrada-Ebel R., Quinn R.J. The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discov., 2015, Vol. 14, no. 2, pp. 111-129.

19. Madhu K., Chanda K., Saji M.J. Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial. Inflammopharmacology, 2013, Vol. 21, no. 2, pp. 129-136.

20. Madsen M.V., Gotzsche Р.C. Acupuncture treatment for pain systematic review of Randomized clinical trials with acupuncture, placebo acupuncture, and acupuncture groups. Br. Med. J., 2009, Vol. 27, pp. 338-346.

21. Miller M.D., Paradis C.F., Honck P.R., Mazumdar S., Stack J.A., Rifai A.H. Rating chronic medical illness burden in geropsychiatric practice and research application of the Cummulative illness Rating Scale. Psychiatry Res., 1992. Vol. 41, no. 3, pp. 237-242.

22. Nakagawa Y., Mukai S., Yamada S., Matsuoka M., Tarumi E., Hashimoto T., Tamura C., Imaizumi A., Nishihira J., Nakamura T. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study. J. Orthop. Sci., 2014, Vol. 19, pp. 933-939.

23. Puenpatom R.A., Victor T.W. Increased prevalenceof metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad. Med., 2009, Vol. 121, pp. 9-20.

24. Roos E.M., Roos H.P., Lohmander L.S., Ekdahl C., Beynnon B.D. Knee Injury andOsteoarthritis Outcome Score (KOOS) – development of a self-administered outcome measure. J. Orthop. Sports Phys. Ther., 1998, no. 28, pp. 88-96.

25. Shirinsky I., Shirinsky V. H1-antihistamines are associated with lower prevalence of radiographic knee osteoarthritis: a cross-sectional analysis of the Osteoarthritis Initiative data. Arthritis Res. Ther., 2018, Vol. 20, 116. doi: 10.1186/s13075-018-1619-7.

26. WHA 67.18 – Traditional Medicine. WHA Resolution; Sixty-seventh World Health Assembly, 2014. Available at: https://apps.who.int/medicinedocs/en/d/Js21462ar/.

27. Witt C., Brinkhaus B., Jena S., Linde K., Streng A., Wagenpfeil S., Hummelsberger J., Walther H.U., Melchart D., Willich S.N. Acupuncture in patients with osteoarthritis of the knee: a randomised trial. Lancet, 2005. Vol. 366, pp. 136-143.